Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Tirzepatide mimics the hormones GLP-1 and GIP, which a person’s stomach produces whenever they eat. These hormones reduce appetite, which can result in weight loss. You must also follow a ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback